Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results

por Mahlangu, Johnny, Luis Lamas, Jose, Cristobal Morales, Juan, Malan, Daniel R., Teeter, John, Charnigo, Robert J., Hwang, Eunhee, Arkin, Steven
Publicado 2022

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

por Mahlangu, Johnny N., Lamas, Jose Luis, Morales, Juan Cristobal, Malan, Daniel R., Šalek, Silva Zupančić, Wang, Michael, Boggio, Lisa N., Hegemann, Inga, Mital, Andrzej, Cardinal, Matthew, Zhu, Tong, Sun, Pengling, Arkin, Steven
Publicado 2022

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

por Clingan, Philip, Ladwa, Rahul, Brungs, Daniel, Harris, Dean Laurence, McGrath, Margaret, Arnold, Susan, Coward, Jermaine, Fourie, Samuel, Kurochkin, Andriy, Malan, Daniel R, Mant, Andrew, Sharma, Vinay, Shue, Hong, Tazbirkova, Andrea, Berciano-Guerrero, Miguel-Angel, Charoentum, Chaiyut, Dalle, Stéphane, Dechaphunkul, Arunee, Dudnichenko, Oleksandr, Koralewski, Piotr, Lugowska, Iwona, Montaudié, Henri, Muñoz-Couselo, Eva, Sriuranpong, Virote, Oliviero, James, Desai, Jayesh
Publicado 2023